• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LU Ningshu, JI Tao, LU Yinglan, et al. Drug delivery strategies and clinical research progress for encephalopathy[J]. J China Pharm Univ, 2024, 55(5): 577 − 589. DOI: 10.11665/j.issn.1000-5048.2024063001
Citation: LU Ningshu, JI Tao, LU Yinglan, et al. Drug delivery strategies and clinical research progress for encephalopathy[J]. J China Pharm Univ, 2024, 55(5): 577 − 589. DOI: 10.11665/j.issn.1000-5048.2024063001
shu

Drug delivery strategies and clinical research progress for encephalopathy

  • 1.

    Department of Pharmaceutics & State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China

  • 2.

    College of Pharmacy, University of Manitoba, Winnipeg MB R3E 0T5, Canada

Funds: This study was supported by the National Natural Science Foundation of China (No. 82372113, No. 82073401); the National High-Level Young Talents Program; and the Natural Science Foundation Outstanding Youth Fund of Jiangsu Province（BK20240096）
More Information
  • Received Date: June 29, 2024
  • Revised Date: July 18, 2024
  • Accepted Date: August 04, 2024
  • Available Online: September 09, 2024
    Graphical Abstract
    • Abstract

  • The blood-brain barrier in humans significantly restricts the effective delivery of drugs into the brain, resulting in poor therapeutic efficacy and difficulty in brain disease management. In recent years, innovative strategies and novel preparations have been studied and developed in order to circumvent the blood-brain barrier, achieve efficient drug entry into the brain, minimize the incidence of peripheral adverse effects, and bring significant therapeutic outcomes to patients. This review summarizes some key development strategies for treating encephalopathy, to provide some insights for the development of the next generation of drugs.

    • FullText(HTML)
    • References (52)
  • [1]
    Wu D, Chen Q, Chen XJ, et al. The blood-brain barrier: structure, regulation, and drug delivery[J]. Signal Transduct Target Ther, 2023, 8(1): 217. doi: 10.1038/s41392-023-01481-w
    [2]
    Chen YX, Wei CX, Lyu YQ, et al. Biomimetic drug-delivery systems for the management of brain diseases[J]. Biomater Sci, 2020, 8(4): 1073-1088. doi: 10.1039/C9BM01395D
    [3]
    Liu XX, Gao T, Lu TS, et al. China Brain Project: from bench to bedside[J]. Sci Bull, 2023, 68(5): 444-447. doi: 10.1016/j.scib.2023.02.023
    [4]
    Chen YX, Qin DT, Zou JH, et al. Living leukocyte-based drug delivery systems[J]. Adv Mater, 2023, 35(17): e2207787. doi: 10.1002/adma.202207787
    [5]
    Huang QQ, Chen YK, Zhang WW, et al. Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases[J]. J Control Release, 2024, 366: 519-534. doi: 10.1016/j.jconrel.2023.12.054
    [6]
    Li GL, Duan SJ, Zhu TT, et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis[J]. J Headache Pain, 2023, 24(1): 129. doi: 10.1186/s10194-023-01662-6
    [7]
    Zhang HQ, Chen Y, Yu M, et al. Nasal delivery of polymeric nanoDisc mobilizes a synergy of central and peripheral amyloid-β clearance to treat Alzheimer’s disease[J]. Proc Natl Acad Sci USA, 2023, 120(51): e2304213120. doi: 10.1073/pnas.2304213120
    [8]
    Zhong L, Wang JJ, Wang P, et al. Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury[J]. Stem Cell Res Ther, 2023, 14(1): 198. doi: 10.1186/s13287-023-03409-1
    [9]
    Xie XY, Song QX, Dai CX, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial[J]. Gen Psychiatr, 2023, 36(5): e101143. doi: 10.1136/gpsych-2023-101143
    [10]
    Shrewsbury SB. The pharmacokinetics of drugs delivered to the upper nasal space[J]. Pharmaceut Med, 2023, 37(6): 451-461.
    [11]
    Shrewsbury SB, Jeleva M, Satterly KH, et al. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 precision olfactory delivery (POD®) device, in healthy adult subjects[J]. Headache, 2019, 59(3): 394-409. doi: 10.1111/head.13476
    [12]
    Liu YX, Wu DW. Bi-directional nasal drug delivery systems: a scoping review of nasal particle deposition patterns and clinical application[J]. Laryngoscope Investig Otolaryngol, 2023, 8(6): 1484-1499. doi: 10.1002/lio2.1190
    [13]
    Rabinowicz AL, Carrazana E, Maggio ET. Improvement of intranasal drug delivery with intravail® alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system[J]. Drugs R D, 2021, 21(4): 361-369. doi: 10.1007/s40268-021-00360-5
    [14]
    Munjal S, Gautam A, Offman E, et al. A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults[J]. Headache, 2016, 56(9): 1455-1465. doi: 10.1111/head.12905
    [15]
    Simões RM, Castro Caldas A, Ferreira JJ. Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease[J]. Expert Rev Clin Pharmacol, 2020, 13(2): 85-101. doi: 10.1080/17512433.2020.1724535
    [16]
    Bilbault T, Taylor S, Walker R, et al. Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters[J]. Ther Deliv, 2016, 7(9): 611-618. doi: 10.4155/tde-2016-0043
    [17]
    Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Neurol, 2020, 19(2): 135-144. doi: 10.1016/S1474-4422(19)30396-5
    [18]
    Li XY, Su ZX, Wang CY, et al. Mapping the evolution of inhaled drug delivery research: trends, collaborations, and emerging frontiers[J]. Drug Discov Today, 2024, 29(2): 103864. doi: 10.1016/j.drudis.2023.103864
    [19]
    Chan JG, Wong J, Zhou QT, et al. Advances in device and formulation technologies for pulmonary drug delivery[J]. AAPS PharmSciTech, 2014, 15(4): 882-897. doi: 10.1208/s12249-014-0114-y
    [20]
    Perucca E, White HS, Bialer M. New GABA-targeting therapies for the treatment of seizures and epilepsy: II. treatments in clinical development[J]. CNS Drugs, 2023, 37(9): 781-795. doi: 10.1007/s40263-023-01025-4
    [21]
    Phatale V, Vaiphei KK, Jha S, et al. Overcoming skin barriers through advanced transdermal drug delivery approaches[J]. J Control Release, 2022, 351: 361-380. doi: 10.1016/j.jconrel.2022.09.025
    [22]
    Braeckman R, Oh C. A study of once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers: a plain language summary[J]. Neurodegener Dis Manag, 2023, 13(6): 303-313. doi: 10.2217/nmt-2023-0012
    [23]
    Tariot PN, Braeckman R, Oh C. Comparison of steady-state pharmacokinetics of donepezil transdermal delivery system with oral donepezil[J]. J Alzheimers Dis, 2022, 90(1): 161-172. doi: 10.3233/JAD-220530
    [24]
    Rossano F, Caiazza C, Sobrino A, et al. Efficacy and safety of selegiline across different psychiatric disorders: a systematic review and meta-analysis of oral and transdermal formulations[J]. Eur Neuropsychopharmacol, 2023, 72: 60-78. doi: 10.1016/j.euroneuro.2023.03.012
    [25]
    Salatin S, Asadi R, Jelvehgari M. Development and characterization of sublingual films for enhanced bioavailability of selegiline hydrochloride[J]. Ther Deliv, 2021, 12(2): 159-174. doi: 10.4155/tde-2020-0118
    [26]
    Pae CU, Lim HK, Han CS, et al. Selegiline transdermal system: current awareness and promise[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31(6): 1153-1163. doi: 10.1016/j.pnpbp.2007.04.020
    [27]
    Fahoum F, Eyal S. Intracerebroventricular administration for delivery of antiseizure therapeutics: challenges and opportunities[J]. Epilepsia, 2023, 64(7): 1750-1765. doi: 10.1111/epi.17625
    [28]
    Schulz A, Specchio N, de los Reyes E, et al. Safety and efficacy of cerliponase Alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study[J]. Lancet Neurol, 2024, 23(1): 60-70. doi: 10.1016/S1474-4422(23)00384-8
    [29]
    Specchio N, Pietrafusa N, Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy[J]. Ther Clin Risk Manag, 2020, 16: 213-222. doi: 10.2147/TCRM.S241048
    [30]
    Kim A, Grover A, Hammon K, et al. Clinical pharmacokinetics and pharmacodynamics of cerliponase Alfa, enzyme replacement therapy for CLN2 disease by intracerebroventricular administration[J]. Clin Transl Sci, 2021, 14(2): 635-644. doi: 10.1111/cts.12925
    [31]
    D’Amico RS, Aghi MK, Vogelbaum MA, et al. Convection-enhanced drug delivery for glioblastoma: a review[J]. J Neurooncol, 2021, 151(3): 415-427. doi: 10.1007/s11060-020-03408-9
    [32]
    Park TY, Jeon J, Cha Y, et al. Past, present, and future of cell replacement therapy for Parkinson’s disease: a novel emphasis on host immune responses[J]. Cell Res, 2024, 34(7): 479-492. doi: 10.1038/s41422-024-00971-y
    [33]
    Johansson ME, Toni I, Kessels RPC, et al. Clinical severity in Parkinson’s disease is determined by decline in cortical compensation[J]. Brain, 2024, 147(3): 871-886. doi: 10.1093/brain/awad325
    [34]
    Lin CY, Lin YC, Huang CY, et al. Ultrasound-responsive neurotrophic factor-loaded microbubble- liposome complex: Preclinical investigation for Parkinson’s disease treatment[J]. J Control Release, 2020, 321: 519-528. doi: 10.1016/j.jconrel.2020.02.044
    [35]
    Rocco MT, Akhter AS, Ehrlich DJ, et al. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease[J]. Mol Ther, 2023, 31(7): 2296. doi: 10.1016/j.ymthe.2023.04.009
    [36]
    Fowler MJ, Cotter JD, Knight BE, et al. Intrathecal drug delivery in the era of nanomedicine[J]. Adv Drug Deliv Rev, 2020, 165/166: 77-95. doi: 10.1016/j.addr.2020.02.006
    [37]
    Reda M, Jabbour R, Haydar A, et al. Case report: rapid recovery after intrathecal rituximab administration in refractory anti-NMDA receptor encephalitis: report of two cases[J]. Front Immunol, 2024, 15: 1369587. doi: 10.3389/fimmu.2024.1369587
    [38]
    Terstappen GC, Meyer AH, Bell RD, et al. Strategies for delivering therapeutics across the blood-brain barrier[J]. Nat Rev Drug Discov, 2021, 20(5): 362-383. doi: 10.1038/s41573-021-00139-y
    [39]
    Liu HJ, Xu PS. Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor[J]. Adv Drug Deliv Rev, 2022, 191: 114619. doi: 10.1016/j.addr.2022.114619
    [40]
    Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp Alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II[J]. Mol Ther, 2021, 29(2): 671-679. doi: 10.1016/j.ymthe.2020.09.039
    [41]
    Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer’s disease[J]. N Engl J Med, 2023, 389(20): 1862-1876. doi: 10.1056/NEJMoa2304430
    [42]
    Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle[J]. Neuron, 2014, 81(1): 49-60. doi: 10.1016/j.neuron.2013.10.061
    [43]
    Grimm HP, Schumacher V, Schäfer M, et al. Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans[J]. MAbs, 2023, 15(1): 2261509. doi: 10.1080/19420862.2023.2261509
    [44]
    Kumthekar P, Tang SC, Brenner AJ, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases[J]. Clin Cancer Res, 2020, 26(12): 2789-2799. doi: 10.1158/1078-0432.CCR-19-3258
    [45]
    Li D, Cho MS, Gonzalez-Delgado R, et al. The effect of ADAMTS13 on graft-versus-host disease[J]. J Cell Mol Med, 2024, 28(13): e18457. doi: 10.1111/jcmm.18457
    [46]
    Lu R, Hollingsworth C, Qiu J, et al. Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis[J]. mBio, 2019, 10(3): e00724-e00719.
    [47]
    Boulware DR, Atukunda M, Kagimu E, et al. Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial[J]. Clin Infect Dis, 2023, 77(12): 1659-1667. doi: 10.1093/cid/ciad440
    [48]
    Liu KY, Howard R. Can we learn lessons from the FDA’s approval of aducanumab[J]? Nat Rev Neurol, 2021, 17(11): 715-722. doi: 10.1038/s41582-021-00557-x
    [49]
    Kong C, Yang EJ, Shin J, et al. Enhanced delivery of a low dose of aducanumab via FUS in 5 × FAD mice, an AD model[J]. Transl Neurodegener, 2022, 11(1): 57. doi: 10.1186/s40035-022-00333-x
    [50]
    Rezai AR, D’Haese PF, Finomore V, et al. Ultrasound blood-brain barrier opening and aducanumab in Alzheimer’s disease[J]. N Engl J Med, 2024, 390(1): 55-62. doi: 10.1056/NEJMoa2308719
    [51]
    Jia YC, Jiang YX, He YL, et al. Approved nanomedicine against diseases[J]. Pharmaceutics, 2023, 15(3): 774. doi: 10.3390/pharmaceutics15030774
    [52]
    Michaud M, Belmatoug N, Catros F, et al. Mucopolysaccharidosis: a review[J]. Rev Med Interne, 2020, 41(3): 180-188. doi: 10.1016/j.revmed.2019.11.010
    • Related Articles

  • Related Articles

    [1]ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904
    [2]ZHU Yinxue, WANG Dexiang, KONG Ying, LU Wenjie, YE Hui, HAO Haiping. Genetic incorporation of unnatural amino acids into proteins and its translational application in biomedicine[J]. Journal of China Pharmaceutical University, 2022, 53(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20220401
    [3]LI Hui, WEN Shuping, HONG Wenrong. Construction of carbamoyltobramcin-producing engineering S.tenebrarius by disruption of aprK gene[J]. Journal of China Pharmaceutical University, 2013, 44(4): 368-373. DOI: 10.11665/j.issn.1000-5048.20130416
    [4]Molecular method for the identification of Bulbus Fritillariae Cirrhosae[J]. Journal of China Pharmaceutical University, 2010, 41(3): 226-230.
    [5]Study on Microwave-assisted Extraction of Active Constituents in Radix Puerariae[J]. Journal of China Pharmaceutical University, 2002, (5): 26-29.
    [6]Fermentation Conditions for High Level Expression of Novel Human Calcitonin Analogue Gene in Engineering Strain[J]. Journal of China Pharmaceutical University, 2000, (2): 74-77.
    [7]ConstitutiveHigh-Expression of the N-Acetylneuraminate Lyase Gene of Escherichia coli[J]. Journal of China Pharmaceutical University, 2000, (1): 68-71.
    [8]Molecular Cloning and Expression of Tryptophanase Gene of Escherichia coli[J]. Journal of China Pharmaceutical University, 1999, (2): 61-64.
    [9]Determination of Molecular Weight of Chitosan by High Performance Gel Permeation Chromatography[J]. Journal of China Pharmaceutical University, 1994, (4): 53-55.
    [10]Molecular Mechanics and Molecular Pharmacology of Cholinergic and Cholinolytic Drugs[J]. Journal of China Pharmaceutical University, 1993, (6): 363-370.

Catalog

    Get Citation
    PDF
    XML
    Article views (1075) PDF downloads (183) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292824

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return